Establishing patient-derived platform to validate putative targets for immunotherapy

• Grant number: 22/15181-0
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: February 01, 2023
• End date: January 31, 2025
• Field of knowledge: Health Sciences - Medicine
• Agreement: GlaxoSmithKline
• Principal Investigator: Kenneth John Gollob
• Grantee: Jaqueline Cristina Fernandes
• Host Institution: Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE). Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE). São Paulo , SP, Brazil
• Company: Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE). Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
• Associated research grant: 21/00408-6 - Center for Research in Immuno-Oncology (CRIO), AP.PCPE

Abstract

The populations of cells, molecules or pathways identified in CRIO as possible targets for therapy will be subjected to preclinical validation using patient-derived organoids (PDO) and xenografts (PDX) in humanized immunodeficient mice. Briefly, to generate the humanized PDX models, NSG mice will be injected with autologous human immune cells and later implanted with previously generated PDX. Tumor organoids will also be co-cultured with cells of the human immune system and characterization will be performed by flow cytometry and immunohistochemistry. The models will be challenged with human immunotherapics to demonstrate the efficiency in reconstituting the immune response. (AU)